2 results match your criteria: "3 Houston Methodist Hospital[Affiliation]"
Neratinib in HER2-Positive Breast Cancer Patients.
Ann Pharmacother
June 2019
1 University of Houston College of Pharmacy, Houston, TX, USA.
Objective: To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of neratinib in human epidermal growth factor receptor (HER2)+ breast cancer (BC).
Data Sources: A PubMed search was performed using the term neratinib between September 12, 2018, and November 21, 2018. References of published articles and reviews were also assessed for additional information.
Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Ann Pharmacother
May 2019
3 Houston Methodist Hospital, Houston, TX, USA.
Objective: To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of ribociclib (LEE011, Kisqali) in hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer.
Data Sources: A PubMed search was performed using the terms 'Ribociclib', 'Kisqali', and 'LEE011' between May 2018 and November 2018. References of published articles and reviews were also assessed for additional information.